STOCK TITAN

If You Invested in TriSalus Life Sciences, Inc. (TLSI)

Healthcare · Medical Devices · NASDAQ
Looking for the current price? See the TLSI quote & overview
$1,000 invested 1 Year Ago
$418
-58.2% price return
-58.2% with dividends reinvested
Bought on Nov 24, 2025 at $5.55 split-adjusted
$1,000 invested 5 Years Ago
$232
-76.8% price return -25.3% CAGR
-76.8% with dividends reinvested
Bought on Nov 22, 2021 at $9.98 split-adjusted
$1,000 invested 10 Years Ago
N/A
Our prices start Feb 8, 2021

What $1,000 or $10,000 in TLSI Would Be Worth Now

Real historical value by amount invested and how long ago
If you invested 1 year ago 5 years ago 10 years ago Since Feb 8, 2021
$1,000 $418 -58% $232 -77% — $221 -78%
$10,000 $4,180 -58% $2,325 -77% — $2,205 -78%

Based on real historical closing prices adjusted for stock splits, without dividends, through 2026-11-20. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.

Custom Calculation

Choose your own date and amount for TLSI

$1,000 Investment Over Time

TLSI vs S&P 500

Year-by-Year Returns

TLSI annual performance
Year Start Price End Price Annual Return Cumulative
2021Feb 8 to Dec 31 $10.52 $9.88 -6.1% -6.1%
2022 $9.88 $10.03 +1.5% -4.7%
2023 $10.03 $8.45 -15.8% -19.7%
2024 $8.45 $5.01 -40.7% -52.4%
2025 $5.01 $6.98 +39.3% -33.7%
2026Dec 31, 2025 to Nov 20 $6.98 $2.32 -66.8% -77.9%

About TriSalus Life Sciences, Inc.

Healthcare · NASDAQ

TriSalus Life Sciences, Inc. (Nasdaq: TLSI) is an oncology-focused medical technology company that concentrates on improving treatment for patients with solid tumors and other difficult-to-treat conditions. According to the company’s public disclosures, its platform combines proprietary drug delivery devices with standard-of-care therapies and a clinical-stage investigational immunotherapy, nelitolimod, a class C Toll-like receptor 9 (TLR9) agonist. TriSalus positions its technology to address challenges that limit the effectiveness of many existing therapies, particularly in liver, pancreatic and other solid tumor settings.

The company reports that its platform includes devices that utilize a proprietary Pressure-Enabled Drug Delivery™ (PEDD™) approach and an investigational immunotherapy. Multiple press releases describe TriSalus as a growing oncology-focused medical technology business that is also exploring applications in non-oncologic conditions where targeted embolization and drug delivery may be beneficial.

Pressure-Enabled Drug Delivery (PEDD) Technology

TriSalus states that its PEDD technology is a novel delivery approach designed to overcome anatomical and physiological barriers that can limit therapeutic delivery. Company materials explain that PEDD modulates pressure and flow during infusion in a way that is intended to deliver more therapeutic agent to the tumor while reducing undesired delivery to normal tissue. This approach is described as particularly relevant for organs such as the liver and pancreas, where high intratumoral pressure, collapsed vasculature and immunosuppressive tumor microenvironments can interfere with effective treatment.

In its descriptions of an “organ-specific platform,” TriSalus highlights two key obstacles it is designed to address: high intratumoral pressure caused by tumor growth and collapsed vasculature, and the immunosuppressive properties of liver and pancreatic tumor immune cells. By systematically targeting these barriers, the company aims to improve response to therapies and enable better patient outcomes.

TriNav Infusion System and Related Devices

TriSalus reports that it has developed FDA-cleared devices that incorporate its PEDD technology. Across multiple releases, the company describes the TriNav® Infusion System as a device for hepatic arterial infusion of liver tumors, and the TriNav Infusion System LV as a variant for hepatic arterial infusion of liver tumors as well. The company also cites a Pancreatic Retrograde Venous Infusion System for pancreatic tumors. These devices are described as using the PEDD approach to deliver a range of therapeutics directly to targeted tissue.

TriSalus also references the launch of TriNav® FLX, which it characterizes as an advancement in its PEDD-based portfolio designed to improve navigability in tortuous vessels. Company commentary notes that TriNav is used in liver embolization and that the PEDD approach is being evaluated in additional embolization applications, including thyroid artery embolization and uterine artery embolization, as described in clinical and key opinion leader event announcements.

Applications in Solid Tumors and Benign Disease

In its public statements, TriSalus consistently describes itself as focused on solid tumors, particularly in the liver and pancreas. The company also notes that its technology is being evaluated in other clinical settings. For example, TriSalus has highlighted investigator-published data on Pressure-Enabled Thyroid Artery Embolization (PED-TAE) using the TriNav Infusion System for symptomatic thyroid disease, including benign thyroid nodules and multinodular goiters. The company states that this minimally invasive technique targets the inferior thyroid arteries to reduce gland size and alleviate symptoms in patients who are not candidates for surgery or conventional therapies.

TriSalus has also announced a clinical trial evaluating genicular artery embolization (GAE) as a potential treatment for knee osteoarthritis, and has discussed the use of its PEDD approach in uterine artery embolization for uterine fibroids. In these communications, the company characterizes itself as bringing its drug delivery technology to both oncologic and non-oncologic conditions where embolization and targeted delivery may offer therapeutic benefit.

Nelitolimod Investigational Immunotherapy

Alongside its devices, TriSalus is developing nelitolimod, a clinical-stage investigational immunotherapeutic candidate described as a class C TLR9 agonist. Company materials state that nelitolimod is designed to treat or improve the immunosuppressive environment created by many tumors, which can render existing immunotherapies ineffective in organs such as the liver and pancreas. TriSalus reports that nelitolimod is being evaluated in Pressure-Enabled Regional Immuno-Oncology™ (PERIO) phase 1 clinical trials where it is delivered via PEDD technology.

The company notes that patient data generated during PERIO clinical trials support the hypothesis that nelitolimod delivered via PEDD may have favorable immune effects within the liver and systemically. It also emphasizes that TLR9, the target of nelitolimod, is expressed across cancer types and that the mechanical barriers addressed by PEDD are commonly present in solid tumors. TriSalus has indicated that it is in the final stages of data completion for several phase 1 trials and plans to explore partnership opportunities for further development.

Commercial Focus and Clinical Adoption

In recent financial updates, TriSalus has described “strong commercial performance” and “growing clinical adoption” of its TriNav product suite and PEDD platform across a broad range of solid tumor indications, with particular emphasis on liver-directed therapies. The company attributes revenue growth to increased use of TriNav in liver embolization and expansion into new embolization applications. It also notes that its commercial efforts are focused on the interventional radiology specialty and that it is investing in registry and other clinical programs to build a data-driven case for expanding PEDD technology into additional clinical settings.

TriSalus has characterized itself as working in partnership with leading cancer centers across the United States and as leveraging immuno-oncology expertise and technology development capabilities. These collaborations are described as supporting both the clinical evaluation of PEDD-based approaches and the broader adoption of its devices in practice.

Capital Structure, Exchange Offer and Emerging Growth Status

TriSalus identifies as an emerging growth company under U.S. securities regulations in multiple Form 8-K filings. In 2025, the company reported an exchange offer and consent solicitation related to its Series A Convertible Preferred Stock, along with a subsequent amendment to the certificate of designations and conversion of preferred shares into common stock. The company has also disclosed actions by its board and compensation committee, including adjustments to executive compensation and equity awards that are tied to achieving specified revenue levels over a defined period.

These filings, together with periodic earnings releases, provide insight into the company’s capital structure, financing strategy and governance decisions, but they do not alter the core description of TriSalus as an oncology-focused medical technology company built around PEDD devices and an investigational immunotherapy.

Position Within Biotechnology and Medical Technology

Within the broader biotechnology and medical technology landscape, TriSalus describes itself as operating at the intersection of drug delivery, interventional oncology and immuno-oncology. Its disclosures emphasize device-based delivery systems integrated with pharmacologic agents, rather than stand-alone therapeutics. The company’s focus on overcoming physical and immunologic barriers in solid tumors, particularly in the liver and pancreas, differentiates its stated approach from more generalized drug development strategies.

TriSalus’ communications consistently highlight its goal of improving therapeutic delivery and clinical outcomes by tailoring both the route and pressure of drug administration, and by pairing this with an immunotherapeutic designed to modify the tumor microenvironment. This combination of device technology and immunotherapy development defines the core of the company’s business model as presented in its public materials.

Market Cap
$143.1M
Current Price
$2.32
EPS (FY2025)
-$1.84
Revenue (FY2025)
$45.2M
Net Margin (FY2025)
-86.9%
View full TLSI overview

Frequently Asked Questions

TriSalus Life Sciences, Inc. investment returns

How much would $1,000 invested in TriSalus Life Sciences, Inc. be worth today?

If you invested $1,000 in TriSalus Life Sciences, Inc. (TLSI) 5 years ago on 2021-11-22, your investment would be worth $232 as of 2026-11-20, a -76.8% price return without dividends, growing at a compounded rate of -25.3% per year (CAGR).

Has TriSalus Life Sciences, Inc. outperformed the S&P 500?

Comparison data requires at least 10 years of trading history. Use the calculator above to compare TLSI performance over available time periods.

What is TriSalus Life Sciences, Inc.'s average annual return?

The compound annual growth rate (CAGR) of TLSI’s share price over the past 5 years is -25.3%, without dividends. Individual years vary a great deal, and TLSI’s best recent full year was 2025 (+39.3%) while the worst was 2024 (-40.7%).

For informational and educational purposes only, not investment advice.